Spine BioPharma Completes Series B Financing

Spine BioPharma completed a $13 million Series B equity financing. Proceeds will support further development of SB-01 For Injection (SB-01, formerly referred to as Remedisc™), a therapeutic for the treatment of degenerative disc disease.

SB-01 is a 7-amino acid chain peptide that binds to and induces downregulation of transforming growth factor,...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0